Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1999-03-05
2000-10-03
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C07D27916, C07D23972, C07D40100, C07D40300
Patent
active
061273600
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to novel diamine derivatives having antihistaminic action and antileukotrienic action and also to medicines containing the same.
BACKGROUND ART
Histamine exhibits bronchial smooth muscle constricting action and capillaropenetration accelerating action as a result of its binding to the H.sub.1 receptor in cell membranes, and is considered to be an important mediator in allergic diseases. Described specifically, histamine is believed to cause aggravation of asthmatic symptoms by its bronchoconstricting action and also to increase transudation of blood components into intercellular spacings due to accelerated capillaropenetration and hence to take part in the formation of edema seen in allergic rhinitis and conjunctivitis. For the treatment of these allergic diseases, antihistaminic agents are therefore used. Conventional antihistaminic agents however bind to the H.sub.1 receptor in the brain, so that side effects on the central nerve system, such as drowsiness, are concerned. In recent years, bronchial asthma is regarded as eosinophilic chronic inflammation of the airway, and a late asthmatic response that the symptom of airway constriction which is typical to asthma is developed due to infiltration of inflammatory cells on the bronchial mucosa, oversecretion of mucus and the like is at issue. Antihistaminic agents are not effective for such late asthmatic responses, leading to the existence of an outstanding desire for the development of pharmaceuticals of a new type for their treatment.
Leukotrienes (LT) are associated with causes for most inflammatory diseases, especially asthma, psoriasis, rheumatism and inflammatory colitis, and are considered to play an important role in inflammatory processes through cytopathy. Leukotrienes are principal mediators of allergy and inflammation, and therefore many substances which inhibit the action and/or syntheses of leukotrienes are being discovered for the treatment of these diseases (S. T. Holgate et al.: J. Allergy Clin. Immunol., 98, 1-13, 1996).
Leukotrienes are arachidonate metabolites synthesized by 5-lipoxygenase (5-LO), and consist of two groups. One of the groups is LTB.sub.4 and has strong chemotaxis towards leukocytes. The other group is collectively called cysteine leukotrienes (CySLT) and includes LTC.sub.4, LTD.sub.4 and LTE.sub.4. As biologically active substances, they have been called "slow-reacting substances of anaphylaxis (SRS-A)" for many years. CysLT binds to their receptors in human tissues to exert its action. A selective LTD.sub.4 receptor inhibitor has been found to inhibit contracting actions of both LTC.sub.4 and LTD.sub.4 in human lung tissues, so that LTC.sub.4 is suggested to bind to the same site of a receptor as LTD.sub.4 (Buckner C. K. et al: Ann. NY Acad. Sci., 524, 181-6, 1988; Aharony D. et al.: New Trends in Lipid Mediators Research, Basel: Karger 67-71, 1989). LTE.sub.4 is also considered to act via the same receptor as LTD.sub.4, but is called a partially active substance for its lower potency.
Described specifically, in an allergic disease such as asthma, an immediate asthmatic response such as bronchial constriction and edematous formation, in which histamine or the like takes principal part, and a late asthmatic response such as airway constriction due to cell infiltration, mucus secretion or mucosal hypertrophy, in which a leukotriene or the like takes part are considered to be important for the development of morbid conditions. In allergic rhinitis, there is similarly a move toward taking each morbid condition as a biphasic response that histamine takes a profound part in an immediate response such as sternutation or nasal oversecretion and leukotriene takes an important part in a late response such as a rhinostenostic symptom due to edema of the nasal mucosa.
A compound having antagonism against both a histamine H.sub.1 receptor and an LTD.sub.4 receptor and less tendency of brain penetration is therefore considered to prevent or cure a variety of allergic diseases, especially a
Onogi Kazuhiro
Tamura Masahiro
Timmerman Henk
Tohma Tsutomu
Wada Yasushi
Kowa Co. Ltd.
Schroeder Ben
Shah Mukund J.
LandOfFree
Diamine derivatives and pharmaceutical containing the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diamine derivatives and pharmaceutical containing the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diamine derivatives and pharmaceutical containing the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-195728